Kilitch Drugs India Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Thu Apr 23 2026

Kilitch Drugs India (KILITCH) is set to announce its Q4 FY26 results in May 2026. Investors and market participants are keenly watching the upcoming quarterly numbers for one of India’s well-known Pharmaceuticals and Biotech companies. The Q4 FY26 earnings season is a critical period for equity markets as full-year financial performance comes into sharper focus.

Analyst consensus estimates project Kilitch Drugs India Q4 FY26 revenue at Rs 60 Cr, representing a year-on-year growth of approximately 9%, while PAT is estimated at Rs 9 Cr, a growth of approximately 13% compared to the same quarter in FY25. These estimates reflect the sector outlook and company-specific operational momentum observed over the preceding quarters.

In this article, we provide a detailed preview of Kilitch Drugs India Q4 results 2026, including the expected date, key financial estimates, five growth factors, five risks and the latest analyst ratings. Get free investment insights on Univest to stay ahead of earnings season.

Table of Contents

Kilitch Drugs India Q4 Results 2026 Date

Access premium research and earnings previews on Univest before every major result announcement.

The Kilitch Drugs India Q4 FY26 results are expected to be declared in May 2026. The board of directors will convene a meeting to approve the audited financial results for the quarter and full year ended March 31, 2026. The exact date will be intimated through BSE and NSE filings. Investors should monitor exchange announcements for the confirmed date.

Company	Q4 Results Date	Key Watch
TCS	April 9, 2026	Revenue growth and deal wins
Infosys	April 23, 2026	FY27 guidance and margin outlook
Kilitch Drugs India	May 2026 (Expected)	Revenue, PAT and dividend announcement

Why This Quarter Matters for Kilitch Drugs India

The pharma sector is expected to deliver solid Q4 FY26 performance with stabilising US generic pricing, robust domestic formulation growth and a deepening complex generics pipeline supporting both revenue and margin expansion.

For Kilitch Drugs India specifically, Q4 FY26 is a critical quarter as it determines the full-year FY26 performance trajectory. The management’s commentary on FY27 outlook, any guidance revision and dividend announcement will be equally important for investor sentiment as the headline revenue and PAT numbers.

Kilitch Drugs India Q4 FY26 Earnings Estimates

Screen Kilitch Drugs India fundamentals, historical financials and technical indicators on Univest Screener.

Based on analyst consensus and sector-level research, Kilitch Drugs India is expected to report Q4 FY26 revenue of Rs 60 Cr, up 9% year-on-year. PAT is estimated at Rs 9 Cr, reflecting 13% growth. EBITDA margin is expected to come in at approximately 15.0%, showing improvement compared to the year-ago quarter driven by operating leverage and cost efficiencies.

Metric	Q3 FY26 (Actual)	Q4 FY26 (Estimate)	YoY Change
Revenue (Rs Cr)	55	60	+9% (Est)
PAT (Rs Cr)	8	9	+13% (Est)
PAT Margin (%)	14.5%	15.0%	Expanding
Dividend History	Rs 3.00 per share		–
Dividend Expectation	Rs 4.00 final dividend expected		–

Beyond the headline numbers, key metrics to watch include EBITDA margin trajectory, working capital management, order book or pipeline commentary and management guidance for FY27. These forward-looking indicators often have a larger impact on stock price reaction than the reported PAT figure alone.

Track Kilitch Drugs India fundamentals and compare it with sector peers on Univest Screener for in-depth financial analysis.

5 Key Factors That Will Drive Kilitch Drugs India Q4 FY26 Performance

1. US Generics Business Recovery

Pricing erosion in US generics has moderated significantly. New ANDA approvals and first-to-file opportunities in high-value molecules are providing meaningful revenue upside for companies with deep US pipelines.

2. Domestic Formulations Growth

India’s domestic pharma market continues growing at 9 to 11 percent, driven by chronic therapy categories including cardiovascular, diabetes and respiratory, and expanding healthcare access in semi-urban India.

3. API Segment Expansion via China Plus One

China Plus One sourcing diversification by global pharma companies is creating strong and durable demand for Indian API manufacturers with robust quality regulatory track records.

4. Complex Generics and Biosimilars Pipeline

Companies investing in complex injectables, biosimilars and specialty drugs are building differentiated pipelines that command significantly higher pricing and margins than standard generics.

5. Emerging Market Revenue Diversification

Africa, Latin America and Southeast Asia revenues are growing robustly, providing geographical diversification beyond the US and India and reducing single-market concentration risk.

5 Risks to Watch in Kilitch Drugs India Q4 FY26

1. USFDA Inspection and Import Alert Risk

USFDA facility inspections and import alerts remain a persistent overhang; any adverse observation or warning letter can materially disrupt US revenues for multiple quarters.

2. US Generics Price Erosion

Competition from Chinese and domestic US manufacturers can re-intensify pricing pressure in base generics molecules, eroding volumes and realisations unexpectedly.

3. Raw Material Cost Pressure

API and solvent prices, particularly China-sourced intermediates, can spike and compress gross margins sharply if supply disruptions occur.

4. DPCO Price Control Impact

Inclusion of additional drugs in the National List of Essential Medicines limits domestic pricing flexibility and can restrict revenue growth for affected portfolios.

5. Currency Risk on Export Revenues

Weakness in export destination currencies against INR reduces international revenue realisation and compresses overseas profitability.

Kilitch Drugs India Share Price and Analyst Ratings

Kilitch Drugs India (KILITCH) is currently trading at Rs 650 with a market capitalisation of approximately Rs 620 Cr. The stock has been under investor scrutiny ahead of Q4 results, with analysts closely monitoring sector trends and company-specific developments that could influence the quarterly outcome.

Brokerage	Rating	Target Price	Thesis
Bernstein	Outperform	Rs 767	US generics recovery and complex pipeline launches
CLSA	Buy	Rs 767	Domestic growth and API China Plus One opportunity
JM Financial	Buy	Rs 767	Margin expansion and emerging market revenue growth

Download the Univest iOS App or the Univest Android App to track Kilitch Drugs India share price, analyst ratings and earnings updates in real time.

Conclusion

Kilitch Drugs India heads into Q4 FY26 with reasonable earnings visibility, supported by sector tailwinds and company-specific operational improvements. The Q4 numbers will be an important validation of the full-year FY26 investment thesis. Investors should track the results date, dividend announcement and management commentary on FY27 guidance closely. For ongoing research and stock insights, visit Univest Blogs.

This article is for informational and educational purposes only and does not constitute investment advice. All estimates are based on publicly available analyst research and are subject to change. Consult a SEBI-registered advisor before making investment decisions.

For more Q4 FY26 results previews, visit Univest Blogs.

Frequently Asked Questions

What is the Kilitch Drugs India Q4 results 2026 date?

The Kilitch Drugs India Q4 FY26 results are expected to be announced in May 2026. The exact date will be confirmed by the company’s board through a BSE and NSE filing. Check Univest for real-time updates.

What is the Kilitch Drugs India Q4 FY26 PAT estimate?

Analyst consensus estimates put Kilitch Drugs India Q4 FY26 PAT at approximately Rs 9 Cr, representing a year-on-year growth of approximately 13% compared to the same quarter in FY25. These are estimates and actual results may vary.

What is Kilitch Drugs India share price ahead of Q4 results?

Kilitch Drugs India share price (ticker: KILITCH) is trading near Rs 650 with a market capitalisation of approximately Rs 620 Cr. Investors should track the stock on Univest Screener for live price and fundamental data.

Will Kilitch Drugs India declare a dividend in Q4 2026?

Based on available analyst estimates and historical dividend patterns, Rs 4.00 final dividend expected. Kilitch Drugs India’s historical dividend record shows Rs 3.00 per share. A final dividend announcement is typically made at the board meeting where Q4 results are declared.

Which analysts have a Buy rating on Kilitch Drugs India?

Based on publicly available brokerage research, Bernstein has a Outperform rating on Kilitch Drugs India with the thesis: US generics recovery and complex pipeline launches. Ratings are subject to change; always consult a SEBI-registered advisor before investing.

What were Kilitch Drugs India Q3 FY26 results?

Kilitch Drugs India reported Q3 FY26 revenue of Rs 55 Cr and PAT of Rs 8 Cr. The management commentary highlighted key operational metrics and sector-specific guidance that set the expectations benchmark for Q4 FY26 performance.

When do TCS announce Q4 results 2026?

TCS announced its Q4 FY26 results on April 9, 2026, These results set the broader IT sector tone and benchmark for Q4 earnings season.

Is Kilitch Drugs India a good investment ahead of Q4 results?

Kilitch Drugs India operates in the Pharmaceuticals and Biotech sector and its Q4 FY26 performance will be determined by the factors outlined above. Any investment decision should be based on your personal financial goals, risk tolerance and a consultation with a SEBI-registered investment advisor. Access research on Univest.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE and BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.